Development of a Prediction Model for Short-Term Remission of Patients with Crohn's Disease Treated with Anti-TNF Drugs

Therapy with anti-tumor necrosis factor (TNF) has dramatically changed the natural history of Crohn's disease (CD). However, these drugs are not without adverse events, and up to 40% of patients could lose efficacy in the long term. We aimed to identify reliable markers of response to anti-TNF...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	International journal of molecular sciences 2023-05, Vol.24 (10), p.8695
Hauptverfasser:	Medina-Medina, Rosario, Iglesias-Flores, Eva, Benítez, Jose M, Marín-Pedrosa, Sandra, Salgueiro-Rodríguez, Isabel, Linares, Clara I, González-Rubio, Sandra, Soto-Escribano, Pilar, Gros, Beatriz, Rodríguez-Perálvarez, Manuel L, Cabriada, José L, Chaparro, María, Gisbert, Javier P, Chicano-Gálvez, Eduardo, Ortea, Ignacio, Ferrín, Gustavo, García-Sánchez, Valle, Aguilar-Melero, Patricia
Format:	Artikel
Sprache:	eng
Schlagworte:	Adalimumab Antineoplastic Agents - therapeutic use Biological products Biomarkers Carbohydrate metabolism Carbohydrates Clinical medicine Comparative analysis Corticosteroids Crohn Disease - drug therapy Crohn's disease Cytokines Cytoskeleton Deregulation Drugs Gender Hemostasis Hemostatics Humans Immune response Immunosuppressive agents Immunotherapy Inflammatory bowel disease Infliximab - therapeutic use Microbiota Multivariate analysis Patients Physiological aspects Plasma Prediction models Prescription drugs Proteins Proteomics Quality of life Remission Remission (Medicine) Remission Induction Steroids Tumor necrosis factor Tumor Necrosis Factor Inhibitors - therapeutic use Tumor Necrosis Factor-alpha - therapeutic use Tumor necrosis factor-TNF Vinculin
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!